You are here

  • Home
  • Archive
  • Volume 68, Issue 5
  • Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
  1. J Askling1,2,
  2. E Baecklund3,
  3. F Granath1,
  4. P Geborek4,
  5. M Fored1,
  6. C Backlin5,
  7. L Bertilsson6,
  8. L Cöster7,
  9. L T Jacobsson8,
  10. S Lindblad2,
  11. J Lysholm9,
  12. S Rantapää-Dahlqvist10,
  13. T Saxne4,
  14. R van Vollenhoven2,
  15. L Klareskog2,
  16. N Feltelius11
  1. 1
    Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
  2. 2
    Rheumatology Unit, Department of Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
  3. 3
    Department of Rheumatology, Uppsala University Hospital, Uppsala, Sweden
  4. 4
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
  5. 5
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
  6. 6
    Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden
  7. 7
    Department of Rheumatology, Linköping University Hospital, Linköping, Sweden
  8. 8
    Department of Rheumatology, Malmö University Hospital, Malmö, Sweden
  9. 9
    Department of Rheumatology, Falu County Hospital, Falun, Sweden
  10. 10
    Department of Rheumatology, University Hospital, Umeå, Sweden
  11. 11
    Medical Products Agency, Uppsala, Sweden
  1. Dr J Askling, Clinical Epidemiology Unit, M9:01, Karolinska Institutet at Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden; johan.askling{at}ki.se

Abstract

Background: Tumour necrosis factor (TNF) antagonists have proved effective as treatment against rheumatoid arthritis (RA), but the unresolved issue of whether the use of anti-TNF therapy increases the already elevated risk of lymphoma in RA remains a concern.

Methods: Using the Swedish Biologics Register (ARTIS), the Swedish Cancer Register, pre-existing RA cohorts and cross-linkage with other national health and census registers, a national RA cohort (n  =  67 743) was assembled and patients who started anti-TNF therapy between 1998 and July 2006 (n  =  6604) were identified. A general population comparator (n  =  471 024) was also assembled and the incidence of lymphomas from 1999 to 31 December 2006 was assessed and compared in these individuals.

Results: Among the 6604 anti-TNF-treated RA patients, 26 malignant lymphomas were observed during 26 981 person-years of follow-up, which corresponded to a relative risk (RR) of 1.35 (95% CI 0.82 to 2.11) versus anti-TNF-naive RA patients (336 lymphomas during 365 026 person-years) and 2.72 (95% CI 1.82 to 4.08) versus the general population comparator (1568 lymphomas during 3 355 849 person-years). RA patients starting anti-TNF therapy in 1998–2001 accounted for the entire increase in lymphoma risk versus the two comparators. By contrast, RR did not vary significantly by time since start of first treatment or with the accumulated duration of treatment, nor with the type of anti-TNF agent.

Conclusion: Overall and as used in routine care against RA, TNF antagonists are not associated with any major further increase in the already elevated lymphoma occurrence in RA. Changes in the selection of patients for treatment may influence the observed risk.

https://doi.org/10.1136/ard.2007.085852

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Funding: Financial support for this study was obtained from the Swedish Cancer Society and from Wyeth-Ayerst, Schering-Plough, Abbott Immunology and Bristol-Myers Squibb. The investigators were in charge of and solely responsible for all data collection, analysis and writing of the manuscript, without any constraints exerted from the agencies or companies that helped to sponsor the study. The South Swedish Anti-TNF Register has received funding from King Gustav V, Österlund and Kock Foundations and from Reumatikerförbundet. Financial support for the Early RA Register was provided by the Swedish National Board of Health and Welfare.

    • Ethics approval: The study was approved by the Ethics Committee at Karolinska Institutet.